Search Results

Marengo Therapeutics, Inc. today announced that its lead program, STAR0602, is the subject of an article published in the latest edition of Science Translational Medicine.

Marengo Therapeutics, Inc. today announced a publication in Science Advances describing the novel immunological effects of its foundational anti-Vβ chain TCR targeting antibodies on human T cells.

This clinical candidate reflects a productive collaboration since the strategic partnership was signed in August 2022.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

Marengo Therapeutics, Inc., a company pioneering novel immuno-therapeutics targeting the T cell receptor (TCR) Vβ to selectively activate the right T cell subsets to fight cancer, today announced the appointment of Kevin Chin, M.D., M.S., as Chief Medical Officer.

Ipsen and Marengo Therapeutics, Inc. announced a strategic partnership to advance two of Marengo’s preclinical STAR platform-generated candidates into the clinic.

Marengo Therapeutics, Inc., a company pioneering novel immuno-therapeutics targeting the T cell receptor (TCR) Vβ repertoire to fight cancer and other diseases, today announced that the company will present a late-breaking abstract at the upcoming American Association for Cancer Research (AACR) Annual Meeting, held April 14-19 in Orlando, Florida.

Gain Therapeutics, Inc. announces that Matthias Alder has departed the Company in order to pursue other opportunities.

Initiates Development of Tailored Innovative Targeted Therapy for Refractory Cancer ReCerise Therapeutics Inc., has announced its selection for a grant from the Ministry of Trade, Industry and Energy of South Korea.

Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today announced plans to accelerate its development initiatives in obesity and cardiometabolic disease through the acquisition of the assets of Better Therapeutics, Inc.